



2215 Yukon St .  
Vancouver, BC  
Canada, V5Y 0A1  
T 1. 604.559.9005  
abcellera.com

## NEWS RELEASE

# AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

5/28/2024

---

VANCOUVER, British Columbia--(BUSINESS WIRE)-- **AbCellera** (Nasdaq: ABCL) today announced that executives from the Company will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 12:20 p.m. Pacific Time (3:20 p.m. Eastern Time).

A live audio webcast of the presentation may be accessed through a link that will be posted on **AbCellera's Investor Relations website**. A replay will be available through the same link following the presentation.

About AbCellera Biologics Inc.

**AbCellera** (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit **www.abcellera.com**.

Inquiries

Media: Kathleen Reid; **media@abcellera.com**, +1(236)521-6774

Business Development: Murray McCutcheon, Ph.D.; **bd@abcellera.com**, +1(604)559-9005

Investor Relations: Melanie Solomon; [ir@abcellera.com](mailto:ir@abcellera.com), +1(778)729-9116

Source: AbCellera Biologics Inc.